Intradermal injection of reduced-dose influenza vaccine was highly immunogenic in persons ⩽60 years of age but less so in persons >60 years

May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p68
Academic Journal
This article reports that intradermal injection of reduced-dose influenza vaccine was highly immunogenic in persons ≤60 years of age but less so in persons >60 years. The study was based on a randomized clinical trial. It found out the immunogenicity of the vaccines assessed with hemagglutination-inhibition (HAI) titers and determined whether it met the guidelines of the European Committee for Proprietary Medicinal Products (CPMP) for annual relicensure of influenza vaccines.


Related Articles

  • Update: Influenza Activity--United States and Worldwide, May-September 2001.  // MMWR: Morbidity & Mortality Weekly Report;9/28/2001, Vol. 50 Issue 38, p822 

    Reports on the influenza activity in the United States (U.S.) and other parts of the world from May to September 25, 2001. Types of influenza viruses reported in various states; Influenza viruses in several continents; Hemagglutination-inhibition titers of influenza B viruses; Optimal time for...

  • Serum Cross-Reactive Antibody Response to a Novel Influenza A (H1N1) Virus After Vaccination with Seasonal Influenza Vaccine.  // MMWR: Morbidity & Mortality Weekly Report;5/22/2009, Vol. 58 Issue 19, p521 

    The article presents a study which examined the response of serum cross-reactive antibody serum to the novel influenza A (H1N1) virus after vaccination with any of four seasonal trivalent, inactivated influenza vaccines (TIV) or with live, attenuated influenza vaccine (LAIV). The study was done...

  • Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data. Nicole E. Basta; M. Elizabeth Halloran; Laura Matrajt; Ira M. Longini // American Journal of Epidemiology;Dec2008, Vol. 168 Issue 12, p1343 

    In this paper, the authors provide estimates of 4 measures of vaccine efficacy for live, attenuated and inactivated influenza vaccine based on secondary analysis of 5 experimental influenza challenge studies in seronegative adults and community-based vaccine trials. The 4 vaccine efficacy...

  • Vaccine Report.  // BioPharm International;Oct2008, Vol. 21 Issue 10, p16 

    The article provides updates related to vaccine in the U.S. Novavax, Inc. of Rockville, Maryland has denoted the prosperous results from the second stage of the Phase 1-2a human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. Its influenza VLPs are produced...

  • Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly. Ruf, B. R.; Colberg, K.; Frick, M.; Preusche, A. // Infection;Aug2004, Vol. 32 Issue 4, p191 

    Background:. An open, randomized, multicenter study was carried out in elderly to compare the immunogenicity and reactogenicity of a conventional influenza split vaccine (SpV) with an MF59-adjuvanted subunit vaccine (aSuV) and a virosome-based subunit vaccine (vSuV) since earlier studies...

  • ASSAY OF INHIBITORS OF INFLUENZA VIRUS HAEMAGGLUTINATION BY ELECTROPHORESIS. Pye, John // Australian Journal of Experimental Biology & Medical Science;Jun1955, Vol. 33 Issue 3, p323 

    Electrophoresis of some inhibitors of influenza virus haemagglutination is described. After destruction of the inhibitory activity with the receptor destroying enzyme of Vibrio cholerae, the electrophoretic patterns of the materials are changed in a manner consistent with a decrease in...

  • Receptor specificity and erythrocyte binding preferences of avian influenza viruses isolated from India. Pawar, Shailesh D.; Parkhi, Saurabh S.; Koratkar, Santosh S.; Mishra, Akhilesh C. // Virology Journal;2012, Vol. 9 Issue 1, p251 

    Introduction: Hemagglutination (HA) and hemagglutination inhibition (HI) assays are conventionally used for detection and identification of influenza viruses. HI assay is also used for detection of antibodies against influenza viruses. Primarily turkey or chicken erythrocytes [red blood cells...

  • Antibody responses to influenza vaccination in patients with chronic renal failure. Osanloo, E. O.; Berlin, B. S.; Popli, S.; Ing, T. S.; Cummings, J. E.; Gandhi, V. C.; Geis, W. P.; Hano, J. E. // Kidney International;Dec1978, Vol. 14 Issue 6, p614 

    A bivalent type A inactivated influenza virus vaccine containing both sets of H3N2 and HSW1N1 antigens was given to patients with chronic renal failure and to control subjects. The patients were divided into an azotemic group in whom dialysis was not yet required and a hemodialyzed group....

  • New Money Scarce, so ITS Founders Chip in $13.4M. Moran, Nuala // BioWorld International;2/24/2010, Vol. 15 Issue 8, p1 

    The article focuses on Immune Targeting Systems (ITS) which raised 13.4 million U.S. dollars to start their Phase I and Phase IIa trials of their universal flu vaccine. Top prospect of the company is flu vaccine FP-01 which is targeted from all seasonal and pandemic influenza virus A strains...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics